fbpx
previous arrow
next arrow
Slider

Premaitha Health plc
(“Premaitha” or the “Group”)

Change of Name to Yourgene Health plc
&
Change of Website Address

Manchester, UK – 7 November 2018: Premaitha Health plc, the international molecular diagnostics group which commercialises genetic products and services that positively impact human health, is pleased to confirm the renaming of the Group as Yourgene Health plc (“Yourgene Health”).

Further to the special resolution approved at the Group’s Annual General Meeting on 25 October 2018, the Group’s name has been changed to Yourgene Health plc and trading in the Group’s shares under the new name and TIDM, “YGEN”, will commence at 8.00 a.m. today. The Group’s website is now available at www.yourgene-health.com.

The change of name reflects the Group’s broadened product development and research service capabilities which extend across the lifecycle of DNA test development and commercialisation.

Yourgene Health’s ongoing strategic priorities include:
•    developing and commercialising genetic products and services that positively impact human health;
•    driving worldwide sales of the Group’s non-invasive prenatal testing (“NIPT”) products and services by targeting further expansion through direct and key distribution channels to expand the geographic footprint;
•    continuing to offer highly customer-focused NIPT products and services which support all types of customer - irrespective of size, geography and market maturity - in partnership with leading DNA technology providers;
•    leveraging the Group’s technical and regulatory expertise and partnerships to extend its genetic testing offering into complementary areas of reproductive health and oncology, both with owned intellectual property and as a third-party collaborator; and
•    supporting diagnostic majors and bioinformatics specialists with in vitro diagnostic product contract development partnerships.

Shareholdings will be unaffected by the change of name and existing share certificates should be retained as they will remain valid for all purposes. Any new share certificates issued will bear the name Yourgene Health plc.

Lyn Rees, Chief Executive Officer of Yourgene Health, commented: “Our change of name to Yourgene Health marks the beginning of an exciting new period for the Group. It reflects our broadened capabilities within the genetic testing universe and the combining of the Premaitha and Yourgene Bioscience businesses.

“Within the NIPT segment, we are aggressively targeting further expansion through distribution and licensing partnerships. The consolidated Group is now well-placed to deliver services to a global market and maximise its revenue potential.

“Our technical expertise in genetic test development, partnerships with DNA technology majors and expanding global footprint also put us in a strong position to develop additional products both within reproductive health and oncology.

“I look forward to providing further updates on the commercialisation of the Group as we expand organically, through distribution and licensing agreements, and via third party partnerships.” 
For more information, please contact:
    
Yourgene Health plc

Lyn Rees, Chief Executive Officer
Barry Hextall, Chief Financial Officer
Joanne Cross, Head of Marketing
This email address is being protected from spambots. You need JavaScript enabled to view it. 
Tel: +44 (0)161 667 1053

Cairn Financial Advisers LLP (NOMAD)
Liam Murray / James Caithie
Tel: +44 (0)20 7213 0880

finnCap (Broker)
Geoff Nash / Matthew Radley (Corporate Finance)
Tim Redfern (Corporate Broking)
Tel: +44 (0)20 7220 0500

Vigo Communications
Ben Simons / Fiona Henson / Antonia Pollock
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: +44 (0)20 7390 0234
 
About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services that positively impact human health. The group works in partnership with global leaders in DNA technology to advance diagnostic science.  

Our product development and research service capabilities extend across the lifecycle of DNA test development including regulatory submissions.

Yourgene Health’s first commercialised products are non-invasive prenatal tests (NIPT) for Down’s syndrome and other genetic disorders, targeting a share of an emerging billion-dollar global market.

Prenatal screening is an established clinical practice, but accuracy challenges with traditional methods are driving the need for NIPT and other DNA-based reproductive health testing solutions. Yourgene Health’s customer-focused products and services support all types of customer, irrespective of size, geography and market maturity. Our commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Through our technical expertise and partnerships, Yourgene Health is aiming to extend its genetic testing offering into complementary areas of reproductive health and oncology.

Yourgene Health is headquartered in Manchester, UK with facilities in Taipei and Singapore. For more information visit www.yourgene-health.com and follow us on twitter www.yourgene-health.com.

  • 30 June 2020 - COVID-19 assay launched +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    COVID-19 assay launched
    Launch of Clarigene™ SARS-CoV-2 test (‘RUO’)

    Manchester, UK – 30 June 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the launch of its Clarigene™ SARS-CoV-2 test for research use only (‘RUO’).

    The Clarigene™ SARS-CoV-2 test is a molecular PCR (polymerase chain reaction) based COVID-19 assay, which detects the SARS-CoV-2 virus RNA* to confirm the presence of the virus. The test

    Read More
  • 16 June 2020 - Collaboration in COVID-19 testing +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Collaboration in COVID-19 testing
    Supporting the effort to get Britain back to work

    Manchester, UK – 16 June 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces a collaboration agreement with international payments company Caxton and immunity passport app Prova, which once launched will support the efforts to get Britain back to work by testing employees for COVID-19.

    The collaboration with Prova and Yourgene

    Read More
  • 15 June 2020 - CE-IVD mark received for Illumina-based IONA® test +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    CE-IVD mark received for Illumina-based IONA ® test
    Non-invasive prenatal screening test to launch as IONA ® Nx

    Manchester, UK – 15 June 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it has received CE-IVD marking for its Illumina-based IONA ® test, the Company’s flagship non-invasive prenatal test (“NIPT”) product for Down’s syndrome and other genetic disorders.

    The newly approved test, the IONA ® Nx NIPT

    Read More
  • 26 May 2020 - Yourgene COVID-19 testing service launch and business update +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Yourgene COVID-19 testing service launch and business update

    Manchester, UK – 26 May 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it has expanded its laboratory capabilities to offer COVID-19 testing service and it is developing its own COVID-19 test kit and targeting a pipeline of opportunities. In addition, the Company provides an update on its wider business activities.

    Yourgene testing laboratories have

    Read More
  • 20 April 2020 - Year-end Trading update: Revenues increase 86% +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Year-end Trading update: Revenues increase 86%

    Manchester, UK – 20 April 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces a trading update for the year ended 31 March 2020.

    Revenues for the year ended 31 March 2020 were £16.6m (2019: £8.9m), up 86% compared to the previous year, and does not include £0.4m of orders for March that fell into the new financial

    Read More
  • 7 April 2020 - Presentation on ‘Adapting during crisis’ +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Presentation on ‘Adapting during crisis’

    Manchester, UK – 7 April 2020: Yourgene Health (AIM: YGEN), a leading international molecular diagnostics group, announces that Hayden Jeffreys, Chief Operating Officer of Yourgene Health, will be presenting at 4pm today at the virtual webinar event ‘Adapting during crisis’ hosted by Bruntwood Sci-Tech.

    Bruntwood Sci-Tech will be joined by its customers from across Manchester and Innovation Birmingham who have adapted

    Read More
  • 25 March 2020 - Contract manufacturing agreement for COVID-19 diagnostic test +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Contract manufacturing agreement for COVID-19 diagnostic test

    Manchester, UK – 25 March 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the signing of an agreement for contract manufacturing services with Novacyt S.A. (“Novacyt”, EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, to support the production of COVID-19 diagnostic tests developed by Primerdesign, Novacyt’s molecular diagnostics division.

    Yourgene will make use

    Read More
  • 10 March 2020 - Acquisition of French distribution channel & Direct Subscription to raise £2.5m +

    THIS ANNOUNCEMENT, INCLUDING THE APPENDICES, AND THE INFORMATION CONTAINED WITHIN THEM, IS RESTRICTED AND IS NOT FOR PUBLIC RELEASE, PUBLICATION, OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.
     
    THIS ANNOUNCEMENT CONTAINS
    Read More
  • 17 February 2020 - CE Marking Technical File submission +

    Yourgene Health plc
    (“Yourgene” or the “Company”)

    CE Marking Technical File submission

    Manchester, UK – 17 February 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it has submitted its CE Marking Technical File for the Illumina-based IONA ® test to its EU notified body, BSI Netherlands.

    BSI Netherlands will now audit the CE Marking Technical File and if accepted will issue a European CE Marking Certificate. As soon as regulatory approvals are received
    Read More
  • 14 February 2020 - Medilink Award win for Outstanding Achievement  +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Medilink Award win for Outstanding Achievement

    Manchester, UK – 14 February 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it has won the Outstanding Achievement Award at the Medilink North of England Healthcare Business Awards 2020, held at the Lowry Hotel in Manchester , yesterday.

    The Outstanding Achievement Award is presented to a Company for an achievement that has had a significant or vital

    Read More
  • 14 February 2020 - TGA approves DPYD for sale in Australia +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    TGA approves DPYD for sale in Australia

    Southern Cross, Yourgene’s Australian distributor , to sell the chemotoxicity diagnostic assay in the Territory

    Manchester, UK – 14 February 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that its chemotoxicity diagnostics assay – Elucigene DPYD - which tests to identify cancer patients at risk of lethal side effects from chemotherapy, has been approved for sale in Australia (‘the

    Read More
  • 5 December 2019 - The Healthcare+ Expo Taiwan +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    The Healthcare+ Expo Taiwan

    Manchester, UK – 5 December 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it will be exhibiting and presenting at The Healthcare+ Expo Taiwan, from the 5-8 December 2019 at stand R241, Hall 2 in the Taipei Nangang Exhibition Centre, Taiwan City, Taiwan.

    The Expo brings together over 600 exhibitors, working in the advanced medicine and leading technology space

    Read More
  • 2 December 2019 - Half-year Report +

    This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. 

    Yourgene Health plc 

    (“Yourgene”, the “Company” or the “Group”) 

    Half-year Report 

    Manchester, UK – 2 December 2019: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces its unaudited half year report for the six months ended 30 September 2019, in line with expectations. 

    The results reflect strong organic growth as well as a

    Read More
  • 29 November 2019 - Bionow Double Award Wins +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Bionow Double Award Wins

    Manchester, UK – 29 November 2019 : Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it has won Bionow Investment Deal of Year and Bionow Company of the Year at the 18th Annual Bionow Awards ceremony, held at The Mere Golf Resort & Spa in Cheshire yesterday.

    The Bionow Investment Deal of Year, sponsored by QIAGEN, is an award presented to

    Read More
  • 28 November 2019 - Opening of New Facilities and Corporate HQ  +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Opening of New Facilities and Corporate HQ  

    Manchester, UK – 28 November 2019:  Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the official opening of its newly integrated facilities and corporate HQ at Citylabs 1.0, in the centre of Manchester’s genomics campus, and continued expansion with a planned further increase in headcount at the Company’s UK headquarters.

    The establishment of the new Company

    Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
Pregnant lady sitting at table with Laptop

Media & Investor Relations
Walbrook PR Ltd
4 Lombard Street
London
EC3V 9HD
yourgene@walbrookpr.com
T : +44 (0)20 7933 8780

Two business people looking at computer screen